BIOGEN INC. Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax
BIOGEN INC. (BIIB) reported Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-12.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax · last filed 2025-02-12
- BIOGEN INC. other comprehensive income (loss), derivative, excluded component, increase (decrease), after adjustments and tax for fiscal 2024 was $0.00.
- BIOGEN INC. other comprehensive income (loss), derivative, excluded component, increase (decrease), after adjustments and tax for fiscal 2023 was $0.00.
- BIOGEN INC. other comprehensive income (loss), derivative, excluded component, increase (decrease), after adjustments and tax for fiscal 2022 was -$25.50M, a 175.00% decline from fiscal 2021.
- BIOGEN INC. other comprehensive income (loss), derivative, excluded component, increase (decrease), after adjustments and tax for fiscal 2021 was $34.00M.
| Period end | Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-12 |
| 2023-12-31 | $0.00 10-K · filed 2025-02-12 |
| 2022-12-31 | -$25.50M 10-K · filed 2025-02-12 |
| 2021-12-31 | $34.00M 10-K · filed 2024-02-14 |
| 2020-12-31 | -$33.60M 10-K · filed 2023-02-15 |
| 2019-12-31 | $21.60M 10-K · filed 2022-02-03 |
| 2018-12-31 | $3.50M 10-K · filed 2021-02-03 |
| 2017-12-31 | $0.00 10-K · filed 2020-02-06 |
| 2016-12-31 | $0.00 10-K · filed 2019-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |